Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Identifieur interne : 000915 ( Main/Exploration ); précédent : 000914; suivant : 000916Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Auteurs : Peter Nash [Australie] ; Bruce Kirkham [Royaume-Uni] ; Masato Okada [Japon] ; Proton Rahman [Canada] ; Benard Combe [France] ; Gerd-Ruediger Burmester [Allemagne] ; David H. Adams [États-Unis] ; Lisa Kerr [États-Unis] ; Chin Lee [États-Unis] ; Catherine L. Shuler [États-Unis] ; Mark Genovese [États-Unis]Source :
- Lancet (London, England) [ 1474-547X ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticorps monoclonaux humanisés (usage thérapeutique), Arthrite psoriasique (traitement médicamenteux), Facteurs de nécrose tumorale (usage thérapeutique), Femelle, Humains, Mâle, Méthode en double aveugle, Produits dermatologiques (usage thérapeutique), Résultat thérapeutique, Santé mondiale.
- MESH :
- traitement médicamenteux : Arthrite psoriasique.
- usage thérapeutique : Anticorps monoclonaux humanisés, Facteurs de nécrose tumorale, Produits dermatologiques.
- Adulte d'âge moyen, Femelle, Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Santé mondiale.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Dermatologic Agents, Tumor Necrosis Factors.
- drug therapy : Arthritis, Psoriatic.
- Double-Blind Method, Female, Global Health, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy and safety of ixekizumab, a monoclonal antibody that selectively targets interleukin-17A, in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor inhibitors.
DOI: 10.1016/S0140-6736(17)31429-0
PubMed: 28551073
Affiliations:
- Allemagne, Australie, Canada, France, Japon, Royaume-Uni, États-Unis
- Angleterre, Berlin, Californie, Grand Londres, Indiana, Région de Kantō
- Berlin, Londres, Tokyo
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B26
- to stream PubMed, to step Curation: 000B23
- to stream PubMed, to step Checkpoint: 000B23
- to stream Ncbi, to step Merge: 004882
- to stream Ncbi, to step Curation: 004882
- to stream Ncbi, to step Checkpoint: 004882
- to stream Main, to step Merge: 000910
- to stream Main, to step Curation: 000915
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.</title><author><name sortKey="Nash, Peter" sort="Nash, Peter" uniqKey="Nash P" first="Peter" last="Nash">Peter Nash</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Queensland, Rheumatology Research Unit, Sunshine Coast, QLD, Australia. Electronic address: drpnash@tpg.com.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Queensland, Rheumatology Research Unit, Sunshine Coast, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kirkham, Bruce" sort="Kirkham, Bruce" uniqKey="Kirkham B" first="Bruce" last="Kirkham">Bruce Kirkham</name><affiliation wicri:level="3"><nlm:affiliation>Guy's and St Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Guy's and St Thomas' NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Okada, Masato" sort="Okada, Masato" uniqKey="Okada M" first="Masato" last="Okada">Masato Okada</name><affiliation wicri:level="3"><nlm:affiliation>Immuno-Rheumatology Center, St Luke's International University, St Luke's International Hospital, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Immuno-Rheumatology Center, St Luke's International University, St Luke's International Hospital, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Rahman, Proton" sort="Rahman, Proton" uniqKey="Rahman P" first="Proton" last="Rahman">Proton Rahman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Memorial University, St Clare's Mercy Hospital, St John's, NL, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Memorial University, St Clare's Mercy Hospital, St John's, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation></author><author><name sortKey="Combe, Benard" sort="Combe, Benard" uniqKey="Combe B" first="Benard" last="Combe">Benard Combe</name><affiliation wicri:level="1"><nlm:affiliation>Departement of Rheumatology, Lapeyronie Hospital, Montpellier Université, Montpelier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departement of Rheumatology, Lapeyronie Hospital, Montpellier Université, Montpelier</wicri:regionArea><wicri:noRegion>Montpelier</wicri:noRegion><wicri:noRegion>Montpelier</wicri:noRegion></affiliation></author><author><name sortKey="Burmester, Gerd Ruediger" sort="Burmester, Gerd Ruediger" uniqKey="Burmester G" first="Gerd-Ruediger" last="Burmester">Gerd-Ruediger Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Campus Mitte, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Campus Mitte, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Adams, David H" sort="Adams, David H" uniqKey="Adams D" first="David H" last="Adams">David H. Adams</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Kerr, Lisa" sort="Kerr, Lisa" uniqKey="Kerr L" first="Lisa" last="Kerr">Lisa Kerr</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Lee, Chin" sort="Lee, Chin" uniqKey="Lee C" first="Chin" last="Lee">Chin Lee</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Shuler, Catherine L" sort="Shuler, Catherine L" uniqKey="Shuler C" first="Catherine L" last="Shuler">Catherine L. Shuler</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Genovese, Mark" sort="Genovese, Mark" uniqKey="Genovese M" first="Mark" last="Genovese">Mark Genovese</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University, Palo Alto, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Stanford University, Palo Alto, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28551073</idno><idno type="pmid">28551073</idno><idno type="doi">10.1016/S0140-6736(17)31429-0</idno><idno type="wicri:Area/PubMed/Corpus">000B26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B26</idno><idno type="wicri:Area/PubMed/Curation">000B23</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B23</idno><idno type="wicri:Area/PubMed/Checkpoint">000B23</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B23</idno><idno type="wicri:Area/Ncbi/Merge">004882</idno><idno type="wicri:Area/Ncbi/Curation">004882</idno><idno type="wicri:Area/Ncbi/Checkpoint">004882</idno><idno type="wicri:Area/Main/Merge">000910</idno><idno type="wicri:Area/Main/Curation">000915</idno><idno type="wicri:Area/Main/Exploration">000915</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.</title><author><name sortKey="Nash, Peter" sort="Nash, Peter" uniqKey="Nash P" first="Peter" last="Nash">Peter Nash</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Queensland, Rheumatology Research Unit, Sunshine Coast, QLD, Australia. Electronic address: drpnash@tpg.com.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Queensland, Rheumatology Research Unit, Sunshine Coast, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kirkham, Bruce" sort="Kirkham, Bruce" uniqKey="Kirkham B" first="Bruce" last="Kirkham">Bruce Kirkham</name><affiliation wicri:level="3"><nlm:affiliation>Guy's and St Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Guy's and St Thomas' NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Okada, Masato" sort="Okada, Masato" uniqKey="Okada M" first="Masato" last="Okada">Masato Okada</name><affiliation wicri:level="3"><nlm:affiliation>Immuno-Rheumatology Center, St Luke's International University, St Luke's International Hospital, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Immuno-Rheumatology Center, St Luke's International University, St Luke's International Hospital, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Rahman, Proton" sort="Rahman, Proton" uniqKey="Rahman P" first="Proton" last="Rahman">Proton Rahman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Memorial University, St Clare's Mercy Hospital, St John's, NL, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Memorial University, St Clare's Mercy Hospital, St John's, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation></author><author><name sortKey="Combe, Benard" sort="Combe, Benard" uniqKey="Combe B" first="Benard" last="Combe">Benard Combe</name><affiliation wicri:level="1"><nlm:affiliation>Departement of Rheumatology, Lapeyronie Hospital, Montpellier Université, Montpelier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departement of Rheumatology, Lapeyronie Hospital, Montpellier Université, Montpelier</wicri:regionArea><wicri:noRegion>Montpelier</wicri:noRegion><wicri:noRegion>Montpelier</wicri:noRegion></affiliation></author><author><name sortKey="Burmester, Gerd Ruediger" sort="Burmester, Gerd Ruediger" uniqKey="Burmester G" first="Gerd-Ruediger" last="Burmester">Gerd-Ruediger Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Campus Mitte, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Campus Mitte, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Adams, David H" sort="Adams, David H" uniqKey="Adams D" first="David H" last="Adams">David H. Adams</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Kerr, Lisa" sort="Kerr, Lisa" uniqKey="Kerr L" first="Lisa" last="Kerr">Lisa Kerr</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Lee, Chin" sort="Lee, Chin" uniqKey="Lee C" first="Chin" last="Lee">Chin Lee</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Shuler, Catherine L" sort="Shuler, Catherine L" uniqKey="Shuler C" first="Catherine L" last="Shuler">Catherine L. Shuler</name><affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Genovese, Mark" sort="Genovese, Mark" uniqKey="Genovese M" first="Mark" last="Genovese">Mark Genovese</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University, Palo Alto, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Stanford University, Palo Alto, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Arthritis, Psoriatic (drug therapy)</term><term>Dermatologic Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Global Health</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Tumor Necrosis Factors (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Arthrite psoriasique (traitement médicamenteux)</term><term>Facteurs de nécrose tumorale (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Produits dermatologiques (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Santé mondiale</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term><term>Tumor Necrosis Factors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Psoriatic</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite psoriasique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Facteurs de nécrose tumorale</term><term>Produits dermatologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Female</term><term>Global Health</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Santé mondiale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy and safety of ixekizumab, a monoclonal antibody that selectively targets interleukin-17A, in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor inhibitors.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Japon</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Berlin</li><li>Californie</li><li>Grand Londres</li><li>Indiana</li><li>Région de Kantō</li></region><settlement><li>Berlin</li><li>Londres</li><li>Tokyo</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Nash, Peter" sort="Nash, Peter" uniqKey="Nash P" first="Peter" last="Nash">Peter Nash</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Kirkham, Bruce" sort="Kirkham, Bruce" uniqKey="Kirkham B" first="Bruce" last="Kirkham">Bruce Kirkham</name></region></country><country name="Japon"><region name="Région de Kantō"><name sortKey="Okada, Masato" sort="Okada, Masato" uniqKey="Okada M" first="Masato" last="Okada">Masato Okada</name></region></country><country name="Canada"><noRegion><name sortKey="Rahman, Proton" sort="Rahman, Proton" uniqKey="Rahman P" first="Proton" last="Rahman">Proton Rahman</name></noRegion></country><country name="France"><noRegion><name sortKey="Combe, Benard" sort="Combe, Benard" uniqKey="Combe B" first="Benard" last="Combe">Benard Combe</name></noRegion></country><country name="Allemagne"><region name="Berlin"><name sortKey="Burmester, Gerd Ruediger" sort="Burmester, Gerd Ruediger" uniqKey="Burmester G" first="Gerd-Ruediger" last="Burmester">Gerd-Ruediger Burmester</name></region></country><country name="États-Unis"><region name="Indiana"><name sortKey="Adams, David H" sort="Adams, David H" uniqKey="Adams D" first="David H" last="Adams">David H. Adams</name></region><name sortKey="Genovese, Mark" sort="Genovese, Mark" uniqKey="Genovese M" first="Mark" last="Genovese">Mark Genovese</name><name sortKey="Kerr, Lisa" sort="Kerr, Lisa" uniqKey="Kerr L" first="Lisa" last="Kerr">Lisa Kerr</name><name sortKey="Lee, Chin" sort="Lee, Chin" uniqKey="Lee C" first="Chin" last="Lee">Chin Lee</name><name sortKey="Shuler, Catherine L" sort="Shuler, Catherine L" uniqKey="Shuler C" first="Catherine L" last="Shuler">Catherine L. Shuler</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000915 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000915 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28551073
|texte= Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28551073" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |